KR20150064091A - 정신의학적 병태의 치료법 - Google Patents

정신의학적 병태의 치료법 Download PDF

Info

Publication number
KR20150064091A
KR20150064091A KR1020157009988A KR20157009988A KR20150064091A KR 20150064091 A KR20150064091 A KR 20150064091A KR 1020157009988 A KR1020157009988 A KR 1020157009988A KR 20157009988 A KR20157009988 A KR 20157009988A KR 20150064091 A KR20150064091 A KR 20150064091A
Authority
KR
South Korea
Prior art keywords
alpha
human
subject
mabp1
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157009988A
Other languages
English (en)
Korean (ko)
Inventor
존 시마드
Original Assignee
엑스바이오테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑스바이오테크, 인크. filed Critical 엑스바이오테크, 인크.
Publication of KR20150064091A publication Critical patent/KR20150064091A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
KR1020157009988A 2012-10-04 2013-10-01 정신의학적 병태의 치료법 Ceased KR20150064091A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261709741P 2012-10-04 2012-10-04
US61/709,741 2012-10-04
PCT/US2013/062899 WO2014055541A1 (en) 2012-10-04 2013-10-01 Treatment of psychiatric conditions

Publications (1)

Publication Number Publication Date
KR20150064091A true KR20150064091A (ko) 2015-06-10

Family

ID=50435375

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157009988A Ceased KR20150064091A (ko) 2012-10-04 2013-10-01 정신의학적 병태의 치료법

Country Status (7)

Country Link
EP (1) EP2903643A4 (enExample)
JP (3) JP6750941B2 (enExample)
KR (1) KR20150064091A (enExample)
CN (1) CN104684581A (enExample)
AU (1) AU2013327498B2 (enExample)
CA (1) CA2886757C (enExample)
WO (1) WO2014055541A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102946904A (zh) 2010-06-18 2013-02-27 埃克斯生物科技公司 关节炎治疗
PH12013500316A1 (en) 2010-08-23 2016-09-02 Janssen Biotech Inc Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
PT2750709T (pt) 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
JP7145162B2 (ja) 2017-02-16 2022-09-30 ヤンセン バイオテク，インコーポレイテッド 化膿性汗腺炎の処置
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
JPWO2024095677A1 (enExample) 2022-11-04 2024-05-10

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9405021D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
US5455234A (en) * 1994-03-16 1995-10-03 Ahluwalia; Gurpreet S. Inhibition of hair growth
JP2002226457A (ja) * 2001-02-02 2002-08-14 Ajinomoto Co Inc 新規シスチン誘導体及び炎症因子活性化抑制剤
HUE029003T2 (en) * 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
NZ593905A (en) * 2009-01-29 2013-03-28 Abbott Lab Il-1 binding proteins
EP2694107B1 (en) * 2011-04-01 2018-08-22 XBiotech, Inc Treatment for dermatological pathologies
US9724409B2 (en) * 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease

Also Published As

Publication number Publication date
JP6750941B2 (ja) 2020-09-02
EP2903643A4 (en) 2016-06-15
JP2022177132A (ja) 2022-11-30
AU2013327498A1 (en) 2015-04-02
CN104684581A (zh) 2015-06-03
JP2020143133A (ja) 2020-09-10
CA2886757A1 (en) 2014-04-10
EP2903643A1 (en) 2015-08-12
JP2015531396A (ja) 2015-11-02
CA2886757C (en) 2022-04-05
WO2014055541A1 (en) 2014-04-10
AU2013327498B2 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
US11191831B2 (en) Treatment of psychiatric conditions
US12116405B2 (en) Arthritis treatment
JP6453278B2 (ja) 皮膚科的病理の治療
CA2886757C (en) Treatment of anxiety with il1.alpha. antagonist
US12037387B2 (en) PAN-ELR+ CXC chemokine antibodies for the treatment of hidradenitis suppurativa
HK40013773A (zh) 皮肤病学病状的治疗
HK1187260A (en) Treatment for dermatological pathologies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150417

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180928

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200221

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201027

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200221

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20201027

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200421

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180928

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20201207

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20201127

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20201027

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200421

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20200221

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180928

X601 Decision of rejection after re-examination
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20210324

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D